These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21741781)

  • 1. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.
    Dunn KE; Sigmon SC; Strain EC; Heil SH; Higgins ST
    Drug Alcohol Depend; 2011 Dec; 119(1-2):1-9. PubMed ID: 21741781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing opioid withdrawal during double-blind buprenorphine detoxification.
    Dunn KE; Saulsgiver KA; Miller ME; Nuzzo PA; Sigmon SC
    Drug Alcohol Depend; 2015 Jun; 151():47-55. PubMed ID: 25823907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine for managing opioid withdrawal.
    Gowing L; Ali R; White JM; Mbewe D
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
    Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
    JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.
    Northrup TF; Stotts AL; Green C; Potter JS; Marino EN; Walker R; Weiss RD; Trivedi M
    Addict Behav; 2015 Feb; 41():20-8. PubMed ID: 25282598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
    Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
    JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.
    Woodcock EA; Lundahl LH; Greenwald MK
    Drug Alcohol Depend; 2015 Jan; 146():89-96. PubMed ID: 25479914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2000; (3):CD002025. PubMed ID: 10908521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gradual dose taper following chronic buprenorphine.
    Becker AB; Strain EC; Bigelow GE; Stitzer ML; Johnson RE
    Am J Addict; 2001; 10(2):111-21. PubMed ID: 11444154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.
    Sanders NC; Mancino MJ; Gentry WB; Guise JB; Bickel WK; Thostenson J; Oliveto AH
    Exp Clin Psychopharmacol; 2013 Aug; 21(4):294-302. PubMed ID: 23855333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002025. PubMed ID: 15495026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous reductions in smoking during double-blind buprenorphine detoxification.
    Patrick ME; Dunn KE; Badger GJ; Heil SH; Higgins ST; Sigmon SC
    Addict Behav; 2014 Sep; 39(9):1353-6. PubMed ID: 24845165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2002; (2):CD002025. PubMed ID: 12076434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
    Amass L; Ling W; Freese TE; Reiber C; Annon JJ; Cohen AJ; McCarty D; Reid MS; Brown LS; Clark C; Ziedonis DM; Krejci J; Stine S; Winhusen T; Brigham G; Babcock D; Muir JA; Buchan BJ; Horton T
    Am J Addict; 2004; 13 Suppl 1(Suppl 1):S42-66. PubMed ID: 15204675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief vs. extended buprenorphine detoxification in a community treatment program: engagement and short-term outcomes.
    Katz EC; Schwartz RP; King S; Highfield DA; O'Grady KE; Billings T; Gandhi D; Weintraub E; Glovinsky D; Barksdale W; Brown BS
    Am J Drug Alcohol Abuse; 2009; 35(2):63-7. PubMed ID: 19199166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naltrexone shortened opioid detoxification with buprenorphine.
    Umbricht A; Montoya ID; Hoover DR; Demuth KL; Chiang CT; Preston KL
    Drug Alcohol Depend; 1999 Oct; 56(3):181-90. PubMed ID: 10529020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.